Cinaciguat

Cinaciguat
Clinical data
Routes of; administration	intravenous (?)
ATC code	none;
Identifiers
	IUPAC name 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl); phenyl]methoxy}phenyl)ethyl]amino}methyl); benzoic acid;
CAS Number	329773-35-5 ;
PubChem CID	9808022;
IUPHAR/BPS	5168;
ChemSpider	7983781 ;
UNII	59K0Y58UAD;
ChEBI	CHEBI:142433;
CompTox Dashboard (EPA)	DTXSID40954614 ;
Chemical and physical data
Formula	C36H39NO5
Molar mass	565.710 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c4ccccc4CCc3ccc(cc3)COc1ccccc1CCN(CCCCC(O)=O)Cc2ccc(C(=O)O)cc2;
	InChI InChI=1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41) ; Key:WPYWMXNXEZFMAK-UHFFFAOYSA-N ;
	(what is this?) (verify)

Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.

Mechanism of action

Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.^[1]

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.